

In re Application of:  
Grotendorst and Neff  
Application No.: 10/658,856  
Filed: September 9, 2003  
Page 3 of 12

PATENT  
Atty Docket No.: FIBRO1130-3

### **Amendments to the Claims**

Please amend claims 15, 22 and 37 as indicated in the listing of claims.

The listing of claims will replace all prior versions, and listings of claims in the application.

### **Listing of Claims:**

1.-14. (Canceled).

15. (Currently amended) An isolated antibody that specifically binds to a C-terminal fragment of connective tissue growth factor (CTGF) polypeptide, but not platelet derived growth factor (PDGF), wherein the antibody inhibits DNA synthesis, and wherein the C-terminal fragment of CTGF ~~consists of an~~ is amino acid residues ~~sequence selected from the group consisting of:~~

- (a) ~~residue~~ 4 through 74 of SEQ ID NO:4; or
- (b) ~~residue~~ 75 through 172 of SEQ ID NO:4; ~~or~~
- (c) ~~residue~~ 4 through 172 of SEQ ID NO:4.

16.-18. (Canceled).

19. (Original) The antibody of claim 15, wherein the antibody is a monoclonal antibody.

20. (Original) The antibody of claim 19, wherein the antibody is a human monoclonal antibody.

In re Application of:  
Grotendorst and Neff  
Application No.: 10/658,856  
Filed: September 9, 2003  
Page 4 of 12

PATENT  
Atty Docket No.: FIBRO1130-3

21. (Original) The antibody of claim 15, wherein the antibody is a polyclonal antibody.

22. (Currently amended) The antibody of claim 15, wherein the antibody ~~comprises murine antigen binding region residues~~ is a murine antibody.

23. (Original) A composition comprising the antibody of claim 15 and a pharmaceutically acceptable excipient or carrier.

24.-36. (Canceled).

37. (Currently amended) The antibody of claim ~~18~~ 15, wherein the antibody is a humanized ~~comprises human antibody residues~~.